Targeted delivery via selective cellular markers can potentially increase the efficacy and
reduce the toxicity of therapeutic agents. The folate receptor (FR) has two glycosyl …

Introduction: Folate receptor− α (FR− α) has been established as a membrane marker for
ovarian cancer. In addition, it is frequently overexpressed in other major types of epithelial …

Folate targeted drug delivery has emerged as an alternative therapy for the treatment and
imaging of many cancers and inflammatory diseases. Due to its small molecular size and …

Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

The vitamin folic acid (FA) enters cells either through a carrier protein, termed the reduced
folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor (FR) …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

Over the last 25+ years, the folate receptor (FR) has emerged as an attractive tumor
biomarker with the potential to be exploited for therapeutic purposes. Increasing evidence …

In normal tissues, the expression of folate receptors is low and limited to cells that are
important for embryonic development or for folate reabsorption. However, in several …

For over a decade the folate receptor has been intensively investigated as a means for
tumor-specific delivery of a broad range of experimental therapies including several …